BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 22926063)

  • 1. BACE1 in Alzheimer's disease.
    Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
    Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
    Stockley JH; O'Neill C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions.
    Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH
    Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
    Sun X; Wang Y; Qing H; Christensen MA; Liu Y; Zhou W; Tong Y; Xiao C; Huang Y; Zhang S; Liu X; Song W
    FASEB J; 2005 May; 19(7):739-49. PubMed ID: 15857888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome.
    Sun X; He G; Song W
    FASEB J; 2006 Jul; 20(9):1369-76. PubMed ID: 16816112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BACE1 structure and function in health and Alzheimer's disease.
    Cole SL; Vassar R
    Curr Alzheimer Res; 2008 Apr; 5(2):100-20. PubMed ID: 18393796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
    Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
    J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.
    Rossner S; Sastre M; Bourne K; Lichtenthaler SF
    Prog Neurobiol; 2006 Jun; 79(2):95-111. PubMed ID: 16904810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.
    Atwal JK; Chen Y; Chiu C; Mortensen DL; Meilandt WJ; Liu Y; Heise CE; Hoyte K; Luk W; Lu Y; Peng K; Wu P; Rouge L; Zhang Y; Lazarus RA; Scearce-Levie K; Wang W; Wu Y; Tessier-Lavigne M; Watts RJ
    Sci Transl Med; 2011 May; 3(84):84ra43. PubMed ID: 21613622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis.
    Tan J; Evin G
    J Neurochem; 2012 Mar; 120(6):869-80. PubMed ID: 22171895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presenilin 1 is involved in the maturation of beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1).
    Kuzuya A; Uemura K; Kitagawa N; Aoyagi N; Kihara T; Ninomiya H; Ishiura S; Takahashi R; Shimohama S
    J Neurosci Res; 2007 Jan; 85(1):153-65. PubMed ID: 17075903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue.
    Coulson DT; Beyer N; Quinn JG; Brockbank S; Hellemans J; Irvine GB; Ravid R; Johnston JA
    J Alzheimers Dis; 2010; 22(4):1111-22. PubMed ID: 20930286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.